Clinical Trials Logo

Clinical Trial Summary

This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. This study will allow enrollment of up to 150 medically stable male and female participants with TD who previously participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.


Clinical Trial Description

This study was terminated after 60 weeks due to the commercial availability of valbenazine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02736955
Study type Interventional
Source Neurocrine Biosciences
Contact
Status Completed
Phase Phase 3
Start date June 13, 2016
Completion date June 30, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT02840760 - Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. N/A
Completed NCT01688037 - NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Phase 2
Completed NCT01391390 - Melatonin Treatment for Tardive Dyskinesia in Schizophrenia N/A
Withdrawn NCT03254186 - Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Phase 2/Phase 3
Completed NCT02291861 - Addressing Involuntary Movements in Tardive Dyskinesia Phase 3
Completed NCT02274558 - A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Phase 3
Completed NCT02198794 - Reducing Involuntary Movements in Participants With Tardive Dyskinesia Phase 3
Completed NCT01467089 - The Assessment of Movement Disorders Utilizing Live Two-Way Video N/A
Completed NCT04794413 - Pimavanserin Treatment in TS Early Phase 1
Recruiting NCT06011408 - Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes N/A
Recruiting NCT05859698 - Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Phase 4
Active, not recruiting NCT02252380 - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders N/A
Terminated NCT00917293 - Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Phase 2
Completed NCT01543321 - Xenazine in Late Dyskinetic Syndrome With Neuroleptics Phase 3
Completed NCT02405091 - Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Phase 3
Completed NCT03176771 - Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Phase 2/Phase 3
Terminated NCT02524886 - Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia N/A
Completed NCT02195700 - Aim to Reduce Movements in Tardive Dyskinesia Phase 2/Phase 3
Completed NCT03497013 - Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia N/A
Withdrawn NCT01908452 - Pyridoxal Kinase Activity in Tardive Dyskinesia Phase 3